Replies to post #13650 on Marker Therapeutics Inc (MRKR)

[Dodger1]

Thank you RK. I was looking at today's stock prices...right on.

[esedu]

Rk, it also cannot be stressed enough that the LEAD vaccine candidate for Tapimmune, TPIV200, is complementary to Galena's Neuvax. While Neuvax will be indicated for HER2 1/2 cancer, TPIV200 is targeting triple negative breast cancer. Both these companies stand to be cornerstones of this new market in breast cancer vaccines. What's good for Galena will be good for TapImmune, and hopefully TPIV's sp will start benefiting from GALE's bull run.

Exciting times!